Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Laboratory MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Amyotrophic lateral sclerosis, 2016: existing therapies and the ongoing search for neuroprotection.Expert Opin Pharmacother. 2016; 17: 1669-1682
- Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.Lancet Neurol. 2017; 16: 505-512
- Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management.CNS Drugs. 2010; 24: 375-398
- The frontotemporal dementia-motor neuron disease continuum.Lancet. 2016; 388: 919-931
- Cognitive impairment, frontotemporal dementia, and the motor neuron diseases.Ann Neurol. 2003; 54: S20-S23
- The overlap of amyotrophic lateral sclerosis and frontotemporal dementia.Neurology. 2002; 59: 1077-1079
- Are amyotrophic lateral sclerosis patients cognitively normal?.Neurology. 2003; 60: 1094-1097
- The anatomy of cognitive impairment in amyotrophic lateral sclerosis: more than frontal lobe dysfunction.Cortex. 2012; 48: 166-182
- Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.Science. 2006; 314: 130-133
- Molecular neuropathology of frontotemporal dementia: insights into disease mechanisms from postmortem studies.J Neurochem. 2016; 138: 54-70
- A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD.Neuron. 2011; 72: 257-268
- Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study.Lancet Neurol. 2012; 11: 323-330
- Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS.Neuron. 2011; 72: 245-256
- C9orf72-FTD/ALS pathogenesis: evidence from human neuropathological studies.Acta Neuropathol. 2019; 137: 1-26
- Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications.Lancet Neurol. 2018; 17: 94-102
- Genetic screening in sporadic ALS and FTD.J Neurol Neurosurg Psychiatry. 2017; 88: 1042-1044
- Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis.Nature. 1993; 362: 59-62
- Neuropathology of amyotrophic lateral sclerosis and its variants.Neurol Clin. 2015; 33: 855-876
- Prevalence of SOD1 mutations in the Italian ALS population.Neurology. 2008; 70: 533-537
- Genetic analysis and SOD1 mutation screening in Iranian amyotrophic lateral sclerosis patients.Neurobiol Aging. 2013; 34: 1516.e1-8
- Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis.J Neurol Neurosurg Psychiatry. 2017; 88: 540-549
- Delineating the genetic heterogeneity of ALS using targeted high-throughput sequencing.J Med Genet. 2013; 50: 776-783
- The D90A mutation results in a polymorphism of Cu, Zn superoxide dismutase that is prevalent in northern Sweden and Finland.Hum Mol Genet. 1995; 4: 1105-1108
- Emerging antisense oligonucleotide and viral therapies for amyotrophic lateral sclerosis.Curr Opin Neurol. 2018; 31: 648-654
- Analyses of the MAPT, PGRN, and C9orf72 mutations in Japanese patients with FTLD, PSP, and CBS.Parkinsonism Relat Disord. 2013; 19: 15-20
- Novel L284R MAPT mutation in a family with an autosomal dominant progressive supranuclear palsy syndrome.Neurodegener Dis. 2011; 8: 149-152
- The tauopathy associated with mutation +3 in intron 10 of Tau: characterization of the MSTD family.Brain. 2008; 131: 72-89
- Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study.Lancet Neurol. 2019; https://doi.org/10.1016/S1474-4422(19)30394-1
- Progranulin Leu271LeufsX10 is one of the most common FTLD and CBS associated mutations worldwide.Neurobiol Dis. 2009; 33: 379-385
- Alzheimer disease-like clinical phenotype in a family with FTDP-17 caused by a MAPT R406W mutation.Eur J Neurol. 2008; 15: 377-385
- Mutational analysis in early-onset familial dementia in the Japanese population. The role of PSEN1 and MAPT R406W mutations.Dement Geriatr Cogn Disord. 2008; 26: 43-49
- Tau (MAPT) mutation Arg406Trp presenting clinically with Alzheimer disease does not share a common founder in Western Europe.Hum Mutat. 2003; 22: 409-411
- Phenotypic variation in hereditary frontotemporal dementia with tau mutations.Ann Neurol. 1999; 46: 617-626
- Autosomal dominant dementia with widespread neurofibrillary tangles.Ann Neurol. 1997; 42: 564-572
- Lower motor neuron disease with respiratory failure caused by a novel MAPT mutation.Neurology. 2014; 82: 1990-1998
- A novel mutation (K317M) in the MAPT gene causes FTDP and motor neuron disease.Neurology. 2005; 64: 1578-1585
- Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia.Nat Genet. 2005; 37: 806-808
- Frontotemporal dementia: a bridge between dementia and neuromuscular disease.Ann N Y Acad Sci. 2015; 1338: 71-93
- Absence of FUS-immunoreactive pathology in frontotemporal dementia linked to chromosome 3 (FTD-3) caused by mutation in the CHMP2B gene.Acta Neuropathol. 2009; 118: 719-720
- Novel types of frontotemporal lobar degeneration: beyond tau and TDP-43.J Mol Neurosci. 2011; 45: 402-408
- C9ORF72 repeat expansions and other FTD gene mutations in a clinical AD patient series from Mayo Clinic.Am J Neurodegener Dis. 2012; 1: 107-118
- Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration.Hum Mol Genet. 2006; 15: 2988-3001
- SQSTM1 mutations in French patients with frontotemporal dementia or frontotemporal dementia with amyotrophic lateral sclerosis.JAMA Neurol. 2013; 70: 1403-1410
- Novel TARDBP mutations in Nordic ALS patients.J Hum Genet. 2012; 57: 316-319
- TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration.Ann Neurol. 2009; 65: 470-473
- Clinical phenotypes and radiological findings in frontotemporal dementia related to TARDBP mutations.J Neurol. 2015; 262: 375-384
- Mutation within TARDBP leads to frontotemporal dementia without motor neuron disease.Hum Mutat. 2009; 30: E974-E983
- TARDBP variation associated with frontotemporal dementia, supranuclear gaze palsy, and chorea.Mov Disord. 2009; 24: 1843-1847
- TARDBP mutation analysis in TDP-43 proteinopathies and deciphering the toxicity of mutant TDP-43.J Alzheimers Dis. 2013; 33: S35-S45
- p.N345K mutation in TARDBP in a patient with familial amyotrophic lateral sclerosis: an autopsy case.Neuropathology. 2019; 39: 286-293
- The role of FUS gene variants in neurodegenerative diseases.Nat Rev Neurol. 2014; 10: 337-348
- TARDBP and FUS mutations associated with amyotrophic lateral sclerosis: summary and update.Hum Mutat. 2013; 34: 812-826
- Frameshift and novel mutations in FUS in familial amyotrophic lateral sclerosis and ALS/dementia.Neurology. 2010; 75: 807-814
- RNA binding proteins and the pathogenesis of frontotemporal lobar degeneration.Annu Rev Pathol. 2019; 14: 469-495
- Valosin-containing protein disease: inclusion body myopathy with Paget’s disease of the bone and fronto-temporal dementia.Neuromuscul Disord. 2009; 19: 308-315
- Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein.Nat Genet. 2004; 36: 377-381
- A pan-European study of the C9orf72 repeat associated with FTLD: geographic prevalence, genomic instability, and intermediate repeats.Hum Mutat. 2013; 34: 363-373
- Cognitive and behavioral features of c9FTD/ALS.Alzheimers Res Ther. 2012; 4: 29
- Clinical and pathological features of familial frontotemporal dementia caused by C9ORF72 mutation on chromosome 9p.Brain. 2012; 135: 709-722
- p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS.Acta Neuropathol. 2011; 122: 691-702
- Age-related penetrance of the C9orf72 repeat expansion.Sci Rep. 2017; 7https://doi.org/10.1038/s41598-017-02364-1
- The C9orf72 hexanucleotide repeat expansion presents a challenge for testing laboratories and genetic counseling.Amyotroph Lateral Scler Frontotemporal Degener. 2019; 20: 310-316
- SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.Neurology. 2012; 79: 1556-1562
- An FTLD-associated SQSTM1 variant impacts Nrf2 and NF-κB signalling and is associated with reduced phosphorylation of p62.Mol Cell Neurosci. 2019; 98: 32-45
- SQSTM1 mutations – bridging Paget disease of bone and ALS/FTLD.Exp Cell Res. 2014; 325: 27-37
- Clinicopathological description of two cases with SQSTM1 gene mutation associated with frontotemporal dementia.Neuropathology. 2016; 36: 27-38
- Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia.Nature. 2011; 477: 211-215
- Making connections: pathology and genetics link amyotrophic lateral sclerosis with frontotemporal lobe dementia.J Mol Neurosci. 2011; 45: 663-675
- Tissue specific induction of p62/Sqstm1 by Farnesoid X receptor.PLoS One. 2012; 7https://doi.org/10.1371/journal.pone.0043961
- The clinical, neuroanatomical, and neuropathologic phenotype of TBK1-associated frontotemporal dementia: a longitudinal case report.Alzheimers Dement (Amst). 2017; 6: 75-81
- Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways.Science. 2015; 347: 1436-1441
- Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia.Nat Neurosci. 2015; 18: 631-636
- Loss of TBK1 is a frequent cause of frontotemporal dementia in a Belgian cohort.Neurology. 2015; 85: 2116-2125
- Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease.Acta Neuropathol. 2015; 130: 77-92
Moreno C, Hoover B, Likanje M, et al. Pathogenic ATXN2 repeat expansions are as common as TARDBP mutations in large ALS cohorts. In: Northeast ALS Consortium Conference, October 4, 2019, Clearwater Beach, FL.
- Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS.Nature. 2010; 466: 1069-1075
- Patients with amyotrophic lateral sclerosis have high interest in and limited access to genetic testing.J Genet Couns. 2017; 26: 604-611
- Patients with sporadic and familial amyotrophic lateral sclerosis found value in genetic testing.Mol Genet Genomic Med. 2018; 6: 224-229
- Alzheimer’s disease and frontotemporal dementia: the current state of genetics and genetic testing since the advent of next-generation sequencing.Mol Diagn Ther. 2018; 22: 505-513
- Genetic testing in ALS: a survey of current practices.Neurology. 2017; 88: 991-999
- Lack of consensus in ALS genetic testing practices and divergent views between ALS clinicians and patients.Amyotroph Lateral Scler Frontotemporal Degener. 2019; 20: 216-221
- Genetic testing and genetic counseling for amyotrophic lateral sclerosis: an update for clinicians.Genet Med. 2017; 19: 267-274
- Comparison of family histories in FTLD subtypes and related tauopathies.Neurology. 2005; 65: 1817-1819
- A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series.Brain. 2008; 131: 706-720
- Comparative analysis of C9orf72 and sporadic disease in an ALS clinic population.Neurology. 2016; 87: 1024-1030
- The presenilin 1 P264L mutation presenting as non-fluent/agrammatic primary progressive aphasia.J Alzheimers Dis. 2013; 36: 239-243
- Familial dementia with frontotemporal features associated with M146V presenilin-1 mutation.Brain Pathol. 2013; 23: 595-600
- The prevalence of frontotemporal dementia.Neurology. 2002; 58: 1615-1621
- Possible precision medicine implications from genetic testing using combined detection of sequence and intragenic copy number variants in a large cohort with childhood epilepsy.Epilepsia Open. 2019; 4: 397-408
- Incidence of pathogenic, likely pathogenic, and uncertain ALS variants in a clinic cohort.Neurol Genet. 2020; 6https://doi.org/10.1212/NXG.0000000000000390
- De novo FUS mutations are the most frequent genetic cause in early-onset German ALS patients.Neurobiol Aging. 2015; 36: 3117.e1-3117.e6
- Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.Genet Med. 2015; 17: 405-424
- A blinded international study on the reliability of genetic testing for GGGGCC-repeat expansions in C9orf72 reveals marked differences in results among 14 laboratories.J Med Genet. 2014; 51: 419-424
- Small deletion in C9orf72 hides a proportion of expansion carriers in FTLD.Neurobiol Aging. 2015; 36: 1601.e1-5
- Variable reporting of C9orf72 and a high rate of uncertain results in ALS genetic testing.Neurol Genet. 2019; 5: e301
- The C9orf72 repeat size correlates with onset age of disease, DNA methylation and transcriptional downregulation of the promoter.Mol Psychiatry. 2016; 21: 1112-1124
Article info
Publication history
Published online: July 02, 2020
Identification
Copyright
© 2020 Elsevier Inc. All rights reserved.
